Suven Life Sciences (BOM:530239) Scaled Net Operating Assets: N/A (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530239 Suven Life Sciences Ltd BOM:530239
41 GF Score
Price ₹306.30
GF Value ₹97.20
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Suven Life Sciences Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Suven Life Sciences's operating assets for the quarter that ended in Mar. 2026 was ₹4,352.83 Mil. Suven Life Sciences's operating liabilities for the quarter that ended in Mar. 2026 was ₹161.20 Mil. Suven Life Sciences's Total Assets for the quarter that ended in Dec. 2025 was ₹0.00 Mil. Therefore, Suven Life Sciences's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.

Suven Life Sciences Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Suven Life Sciences's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suven Life Sciences Scaled Net Operating Assets Chart

Suven Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 2.72 0.46 0.26 3.10

Suven Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:530239 vs ZTS: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Suven Life Sciences Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Scaled Net Operating Assets falls into.


BOM:530239
41GF Score
Suven Life Sciences Ltd BOM:530239
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suven Life Sciences Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Suven Life Sciences's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(4352.833-161.2)/1351.833
=3.10

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6242.14 - 1889.307
=4352.833

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=328.142 - 121.449 - 45.493
=161.2

Suven Life Sciences's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(4352.833-161.2)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=6242.14 - 1889.307
=4352.833

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=328.142 - 121.449 - 45.493
=161.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Suven Life Sciences (BOM:530239) Overvalued in 2026?

Based on GuruFocus' analysis, Suven Life Sciences stock appears to be overvalued. The current stock price of ₹306.30 is trading 215.1% above its estimated GF Value™ of ₹97.20. GuruFocus considers Suven Life Sciences to be Significantly Overvalued.

Key valuation signals for BOM:530239:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹97.20 vs. price of ₹306.30 (215.1% above fair value)
  • GF Score™: 41/100 with 6 warning signs

No single metric tells the full story. See the BOM:530239 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Suven Life Sciences Business Description

Other Exchanges SUVEN:India
Address Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.
41GF Score

Get the complete analysis for BOM:530239

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹306.30
Price
₹97.20
GF Value